Ablynx appoints Hennie Hoogenboom as Chief Scientific Officer

22-Aug-2005

Ablynx, a pioneer in the discovery and development of Nanobodies(TM), a novel class of antibody-derived therapeutic proteins, announced the appointment of Dr Hennie Hoogenboom as Chief Scientific Officer.

Dr Hoogenboom brings nearly 20 years of experience in antibody discovery and engineering. During his career he has led numerous research initiatives involving the discovery of recombinant antibodies and other proteins for therapy in the fields of oncology and inflammation. Previous positions include Senior Vice President Discovery of Dyax Corp, founder of Target Quest BV, associate professor at the University of Maastricht and group leader at Cambridge Antibody Technology Ltd.

Dr Hoogenboom is an inventor on more than 20 patent families. He holds a PhD in antibody engineering and worked as a postdoctoral fellow with Sir Gregory Winter at the MRC, where he co-invented phage display technology for the isolation and engineering of human antibodies.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous